| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5928bea675298a9603b2884afa1915f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44d565daa6023c0bf3fe2ad296c34be4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec3d7a9a543c4214ef75cdabb2d0e04b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d1b3e2becced22c0ed28c2ab3900e33 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96466
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6475 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 |
| filingDate |
1999-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e26784ee675ddfb7502ce80e0dbc79e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30945aaed86504eaffc660bc55fc7c99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66f27b7a7b7663d7a649394a74a71a07 |
| publicationDate |
2000-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0039347-A1 |
| titleOfInvention |
A tumor suppressor protein involved in death signaling, and diagnostics, therapeutics, and screening based on this protein |
| abstract |
The present invention relates to identification of tumor suppressor activity of a protein, caspase-8(CASP8), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation that results from genomic methylation of the promoter. In particular, CASP8 is functionally inactivated in greater than 90 % of all MYCN amplified neuroblastoma cell lines analyzed. Inactivation of CASP8 was observed to occur by homozygous deletion, heterozygous deletion coupled with gene silencing by methylation, and homozygous gene silencing by methylation. A PCR methylation analysis for inactivation of CASP8 is described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108431226-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111378010-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03013591-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02070742-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1283052-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03013591-A3 |
| priorityDate |
1998-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |